Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Type of study
Language
Publication year range
1.
J Hypertens ; 24(6): 1147-55, 2006 Jun.
Article in English | MEDLINE | ID: mdl-16685215

ABSTRACT

BACKGROUND: In-vivo investigation of aldosterone-synthase inhibitors requires experimental models to characterize the biological effects of these compounds. METHODS: Seven successive experiments were performed in groups of 2-month-old male spontaneously hypertensive rats. Urinary free aldosterone was the main end-point measured during two contrasted diets: low sodium-high potassium (LS), inducing high urinary aldosterone (839 pmol/24 h, 95% confidence interval 654-1077), and high sodium-normal potassium (HS), inducing low urinary aldosterone (38.1 pmol/24 h; 95% confidence interval, 32.4-44.9). RESULTS: FAD 286 A (10 and 30 mg/kg) decreased urinary free aldosterone by 53 and 87% on the LS diet, and 50 and 75% on the HS. Plasma renin concentration increased three-fold after a 4-week treatment of 30 mg/kg FAD 286 A on the LS diet and did not change on the HS. The combination of FAD 286 A (30 mg/kg) and spironolactone (30 mg/kg) on the LS diet induced a biological picture of severe hypoaldosteronism and was not tolerated, whereas the HS diet prevented these abnormalities. The combination of FAD 286 A (30 mg/kg) and furosemide (30 mg/kg) on the HS diet corrected the diuretic-induced hypokalemia (4.1 +/- 0.2 versus 3.7 +/- 2.2 mEq/l, P < 0.033). CONCLUSION: This experimental model will be useful to screen future aldosterone-synthase inhibitors and study their biological effects in various experimental conditions.


Subject(s)
Body Weight/drug effects , Cytochrome P-450 CYP11B2/antagonists & inhibitors , Fadrozole/analogs & derivatives , Fadrozole/pharmacology , Renin-Angiotensin System/drug effects , Aldosterone/blood , Aldosterone/urine , Animals , Blood Pressure/drug effects , Diuretics/adverse effects , Diuretics/pharmacology , Dose-Response Relationship, Drug , Drug Interactions/physiology , Furosemide/adverse effects , Furosemide/pharmacology , Hypokalemia/etiology , Male , Mineralocorticoid Receptor Antagonists , Potassium/blood , Potassium, Dietary/pharmacology , Rats , Rats, Inbred SHR , Sodium/blood , Sodium, Dietary/pharmacology , Urea/blood
2.
J Hypertens ; 22(3): 619-27, 2004 Mar.
Article in English | MEDLINE | ID: mdl-15076169

ABSTRACT

OBJECTIVE: To elucidate the mechanisms responsible for the adverse renal effects induced by dual blockade of the renin-angiotensin system (RAS) and the role of salt therein. METHODS: The effects of enalapril, losartan and their combination on blood pressure, renal haemodynamics, renal function and RAS were investigated over a wide range of doses in spontaneously hypertensive rats fed either a low-sodium or a high-sodium diet. RESULTS: In rats fed the low-sodium diet, the losartan-enalapril combination induced the same dose-dependent haemodynamic and hormonal changes as did three- to 10-fold greater doses of enalapril or losartan alone. When a strong decrease (> 50%) in blood pressure was achieved (with 10 mg/kg enalapril plus 10 mg/kg losartan, 100 mg/kg enalapril or 100 mg/kg losartan), a massive renal vasoplegia occurred and renal insufficiency developed. In addition, because of the huge release of renin, angiotensinogen concentrations were reduced, leading to a decrease in intrarenal angiotensins. In rats fed the high-sodium diet, those treated with the enalapril 30 mg/kg plus losartan 30 mg/kg combination, despite complete functional RAS blockade, exhibited smaller decreases in blood pressure and renal resistance, lesser release of renin and angiotensinogen consumption, and a normal renal function. These effects were similar to those produced by 100 mg/kg of enalapril or losartan in rats fed the high-salt diet, or by 10 mg/kg of enalapril or of losartan in rats fed the low-salt diet. CONCLUSIONS: Dual RAS blockade could be either beneficial, when sodium intake is unrestricted, or dangerous, when sodium intake is restricted.


Subject(s)
Angiotensin-Converting Enzyme Inhibitors/pharmacology , Antihypertensive Agents/pharmacology , Enalapril/pharmacology , Hypertension, Renal/drug therapy , Losartan/pharmacology , Sodium Chloride, Dietary/pharmacology , Anesthesia , Animals , Blood Pressure/drug effects , Body Weight , Consciousness , Drug Therapy, Combination , Hypertension, Renal/physiopathology , Kidney/physiology , Male , Rats , Rats, Inbred SHR , Renal Circulation/drug effects , Renin-Angiotensin System/drug effects
SELECTION OF CITATIONS
SEARCH DETAIL
...